SCHEMBL2214718

SCHEMBL2214718

CCN=c1scc(-c2ccc(OCCCC(=O)NC3CCN(Cc4ccc(Cl)c(Cl)c4)CC3)cc2)n1CC

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 3/20 0.48
CCR3 P51677 3/20 0.47
CCR1 P32246 2/20 0.47
HRH3 Q9Y5N1 2/20 0.46
PDE3B Q13370 1/20 0.46
PDE3A Q14432 1/20 0.46
SIGMAR1 Q99720 2/20 0.46
MCHR1 Q99705 2/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
HTR2A P28223 1/20 0.41
MMP1 P03956 1/20 0.40
MMP9 P14780 1/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12510967 0.89 UTS2R (0.46) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL2214722 0.87 UTS2R (0.45) UTS2RCCR3CCR1MCHR1MEN1
SCHEMBL2210528 0.86 UTS2R (0.49) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL2214913 0.81 SIGMAR1 (0.49) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL2213964 0.80 SIGMAR1 (0.50) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL2214719 0.79 UTS2R (0.48) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL12510965 0.78 UTS2R (0.49) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL2213240 0.78 USP2 (0.62) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL2213070 0.78 UTS2R (0.64) UTS2RCCR3CCR1HRH3PDE3B
SCHEMBL12511629 0.77 UTS2R (0.48) UTS2RCCR3CCR1HRH3PDE3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1389616-B1 3,4-Dihalobenzylpiperidine derivatives and their medical use MITSUBISHI TANABE PHARMA CORP (JP) 2011-07-27 EP disclosed
US-7115635-B2 Benzylpiperidine compound MITSUBISHI PHARMA CORPORATION (JP) 2006-10-03 US disclosed
US-20040158071-A1 Chemokine inhibitors and stability in blood MITSUBISHI PHARMA CORPORATION (JP) 2004-08-12 US disclosed
EP-1389616-A1 NOVEL BENZYLPIPERIDINE COMPOUND Mitsubishi Pharma Corporation (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158071-A1 Chemokine inhibitors and stability in blood CCL2, CXCR1, CCR5 UTS2R 2154/4885CCR3 21/4885CCR1 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.